Missing the Warning Signs: The Urgent Case for Better Kidney Screening in Diabetes

Early diabetic kidney disease (DKD) acts as a silent saboteur, progressively damaging organs without obvious symptoms until it becomes a leading cause of chronic kidney failure. While international guidelines unequivocally recommend annual screening using urine albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR), a new review highlights a worrying disconnect in patient care. Data, including a study of over 1,000 patients, reveals that adherence to these checks remains persistently low, particularly in tertiary care settings.

The review identifies systemic failures—such as fragmented workflows, limited clinician awareness, and inadequate policy incentives—as the primary barriers. This gap is especially critical now that the therapeutic landscape has evolved. We have powerful tools, including RAAS inhibitors, SGLT2 inhibitors, and non-steroidal mineralocorticoid receptor antagonists (nsMRAs), which can significantly optimise outcomes if introduced early. Experts argue that bridging this gap requires a system-wide overhaul, integrating electronic health record optimisation, multidisciplinary collaboration, and better professional education to embed kidney health firmly within diabetes management.